Bridgeway Capital Management, LLC Larimar Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.2 - $13.28 $147,000 - $464,800	-35,000 Reduced 29.29%	84,500 $641,000
Q4 2023 Feb 14, 2024	BUY	$2.35 - $4.71 $15,745 - $31,557	6,700 Added 5.94%	119,500 $543,000
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $77,000 - $112,250	-25,000 Reduced 18.14%	112,800 $445,000
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $300,000 - $501,000	75,000 Added 119.43%	137,800 $624,000
Q4 2022 Feb 14, 2023	SELL	$2.73 - $5.08 $160,521 - $298,698	-58,799 Reduced 48.35%	62,800 $259,000
Q2 2022 Aug 15, 2022	BUY	$1.9 - $3.98 $111,718 - $234,020	58,799 Added 93.63%	121,599 $238,000
Q4 2021 Feb 14, 2022	BUY	$8.86 - $13.47 $556,408 - $845,916	62,800 New	62,800 $678,000
Q2 2021 Aug 16, 2021	SELL	$8.0 - $15.2 $160,000 - $304,000	-20,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.61 - $22.19 $292,200 - $443,800	20,000 New	20,000 $292,000
Q4 2020 Feb 16, 2021	SELL	$14.28 - $25.06 $146,370 - $256,865	-10,250 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.5 - $17.6 $107,625 - $180,400	10,250 New	10,250 $155,000

127

67.3M

280K

76.3K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $157M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.